Abstract

The type VI secretion system (T6SS) secretes antibacterial effectors into target competitors. Salmonella spp. encode five phylogenetically distinct T6SSs. Here we characterize the function of the SPI-22 T6SS of Salmonella bongori showing that it has antibacterial activity and identify a group of antibacterial T6SS effectors (TseV1-4) containing an N-terminal PAAR-like domain and a C-terminal VRR-Nuc domain encoded next to cognate immunity proteins with a DUF3396 domain (TsiV1-4). TseV2 and TseV3 are toxic when expressed in Escherichia coli and bacterial competition assays confirm that TseV2 and TseV3 are secreted by the SPI-22 T6SS. Phylogenetic analysis reveals that TseV1-4 are evolutionarily related to enzymes involved in DNA repair. TseV3 recognizes specific DNA structures and preferentially cleave splayed arms, generating DNA double-strand breaks and inducing the SOS response in target cells. The crystal structure of the TseV3:TsiV3 complex reveals that the immunity protein likely blocks the effector interaction with the DNA substrate. These results expand our knowledge on the function of Salmonella pathogenicity islands, the evolution of toxins used in biological conflicts, and the endogenous mechanisms regulating the activity of these toxins.

Data availability

All data generated during this study are included in the manuscript and supporting files. Source data files have been provided.

Article and author information

Author details

  1. Julia Takuno Hespanhol

    Departamento de Microbiologia, Universidade de São Paulo, Sao Paulo, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  2. Daniel Enrique Sanchez-Limache

    Departamento de Microbiologia, Universidade de São Paulo, Sao Paulo, Brazil
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1364-7527
  3. Gianlucca Gonçalves Nicastro

    Departamento de Microbiologia, Universidade de São Paulo, Sao Paulo, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  4. Liam Mead

    Department of Biosciences, University of Birmingham, Birmingham, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Edgar Enrique Llontop

    Departamento de Bioquímica, Universidade de São Paulo, Sao Paulo, Brazil
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4910-9667
  6. Gustavo Chagas-Santos

    Departamento de Microbiologia, Universidade de São Paulo, Sao Paulo, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  7. Chuck Shaker Farah

    Departamento de Bioquímica, Universidade de São Paulo, Sao Paulo, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  8. Robson Francisco de Souza

    Departamento de Microbiologia, Universidade de São Paulo, Sao Paulo, Brazil
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5284-4630
  9. Rodrigo da Silva Galhardo

    Departamento de Microbiologia, Universidade de São Paulo, Sao Paulo, Brazil
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5686-9704
  10. Andrew Lovering

    Department of Biosciences, University of Birmingham, Birmingham, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Ethel Bayer-Santos

    Departamento de Microbiologia, Universidade de São Paulo, Sao Paulo, Brazil
    For correspondence
    ebayersantos@usp.br
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3832-3449

Funding

Sao Paulo Research foundation (2016/09047-8)

  • Robson Francisco de Souza

FAPESP Fellowship (2018/04553-8)

  • Ethel Bayer-Santos

MIBTP Studentship

  • Liam Mead

Sao Paulo Research Foundation (2017/17303-7)

  • Chuck Shaker Farah

Sao Paulo Research Foundation (2017/02178-2)

  • Ethel Bayer-Santos

Welcome Trust (209437/Z/17/Z)

  • Andrew Lovering

FAPESP Fellowship (2018/25316-4)

  • Julia Takuno Hespanhol

FAPESP Fellowship (2019/22715-8)

  • Daniel Enrique Sanchez-Limache

FAPESP Fellowship (2021/03400-6)

  • Gianlucca Gonçalves Nicastro

FAPESP Fellowship (2019/12234-2)

  • Edgar Enrique Llontop

FAPESP Fellowship (2020/15389-4)

  • Gustavo Chagas-Santos

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Sophie Helaine, Harvard Medical School, United States

Version history

  1. Preprint posted: December 26, 2021 (view preprint)
  2. Received: August 3, 2022
  3. Accepted: October 9, 2022
  4. Accepted Manuscript published: October 13, 2022 (version 1)
  5. Version of Record published: November 4, 2022 (version 2)

Copyright

© 2022, Hespanhol et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,193
    Page views
  • 417
    Downloads
  • 9
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Julia Takuno Hespanhol
  2. Daniel Enrique Sanchez-Limache
  3. Gianlucca Gonçalves Nicastro
  4. Liam Mead
  5. Edgar Enrique Llontop
  6. Gustavo Chagas-Santos
  7. Chuck Shaker Farah
  8. Robson Francisco de Souza
  9. Rodrigo da Silva Galhardo
  10. Andrew Lovering
  11. Ethel Bayer-Santos
(2022)
Antibacterial T6SS effectors with a VRR-Nuc domain are structure-specific nucleases
eLife 11:e82437.
https://doi.org/10.7554/eLife.82437

Share this article

https://doi.org/10.7554/eLife.82437

Further reading

    1. Microbiology and Infectious Disease
    Nguyen Thi Khanh Nhu, Minh-Duy Phan ... Mark A Schembri
    Research Article

    Neonatal meningitis is a devastating disease associated with high mortality and neurological sequelae. Escherichia coli is the second most common cause of neonatal meningitis in full-term infants (herein NMEC) and the most common cause of meningitis in preterm neonates. Here, we investigated the genomic relatedness of a collection of 58 NMEC isolates spanning 1974–2020 and isolated from seven different geographic regions. We show NMEC are comprised of diverse sequence types (STs), with ST95 (34.5%) and ST1193 (15.5%) the most common. No single virulence gene profile was conserved in all isolates; however, genes encoding fimbrial adhesins, iron acquisition systems, the K1 capsule, and O antigen types O18, O75, and O2 were most prevalent. Antibiotic resistance genes occurred infrequently in our collection. We also monitored the infection dynamics in three patients that suffered recrudescent invasive infection caused by the original infecting isolate despite appropriate antibiotic treatment based on antibiogram profile and resistance genotype. These patients exhibited severe gut dysbiosis. In one patient, the causative NMEC isolate was also detected in the fecal flora at the time of the second infection episode and after treatment. Thus, although antibiotics are the standard of care for NMEC treatment, our data suggest that failure to eliminate the causative NMEC that resides intestinally can lead to the existence of a refractory reservoir that may seed recrudescent infection.

    1. Microbiology and Infectious Disease
    Swati Jain, Gherman Uritskiy ... Venigalla B Rao
    Research Article

    A productive HIV-1 infection in humans is often established by transmission and propagation of a single transmitted/founder (T/F) virus, which then evolves into a complex mixture of variants during the lifetime of infection. An effective HIV-1 vaccine should elicit broad immune responses in order to block the entry of diverse T/F viruses. Currently, no such vaccine exists. An in-depth study of escape variants emerging under host immune pressure during very early stages of infection might provide insights into such a HIV-1 vaccine design. Here, in a rare longitudinal study involving HIV-1 infected individuals just days after infection in the absence of antiretroviral therapy, we discovered a remarkable genetic shift that resulted in near complete disappearance of the original T/F virus and appearance of a variant with H173Y mutation in the variable V2 domain of the HIV-1 envelope protein. This coincided with the disappearance of the first wave of strictly H173-specific antibodies and emergence of a second wave of Y173-specific antibodies with increased breadth. Structural analyses indicated conformational dynamism of the envelope protein which likely allowed selection of escape variants with a conformational switch in the V2 domain from an α-helix (H173) to a β-strand (Y173) and induction of broadly reactive antibody responses. This differential breadth due to a single mutational change was also recapitulated in a mouse model. Rationally designed combinatorial libraries containing 54 conformational variants of V2 domain around position 173 further demonstrated increased breadth of antibody responses elicited to diverse HIV-1 envelope proteins. These results offer new insights into designing broadly effective HIV-1 vaccines.